Skip to main content
Carisma Therapeutics Inc. logo

Carisma Therapeutics Inc. — Investor Relations & Filings

Ticker · CARM ISIN · US14216R1014 LEI · 549300DGKHONOZQIY116 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2024-06-14 Declaration of Voting R…
Country US United States of America
Listing US CARM

About Carisma Therapeutics Inc.

https://sesenbio.com/

Carisma Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of engineered macrophage-based therapeutics. The company's proprietary cell therapy platform is centered on Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes. This approach is designed to leverage the unique abilities of macrophages to infiltrate solid tumors, overcome the immunosuppressive tumor microenvironment, and stimulate a broad anti-tumor response. Carisma's pipeline is focused on developing treatments for cancer and other serious disorders, including fibrosis.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 14, 2024. It details the submission of matters to a vote of security holders at the company's reconvened virtual annual meeting, including election of directors, advisory vote on executive compensation, and ratification of the independent auditor. The content focuses on the official results of shareholder votes at the annual meeting. The document length is 4432 characters, which is relatively short and primarily reports voting outcomes rather than the full AGM materials or presentations. Therefore, this filing corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-06-14 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2024, by Carisma Therapeutics Inc. The content focuses on Item 5.02, which relates to the departure, election, or appointment of directors or officers and compensatory arrangements. Specifically, it details special retention stock option grants to named executive officers. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is an announcement of management changes and compensation arrangements. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4640 characters, which is consistent with a typical 8-K filing for management changes and compensation disclosures.
2024-06-14 English
SC 13D/A
Major Shareholding Notification
2024-05-29 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2024, by Carisma Therapeutics Inc. It announces the company's financial results for the quarter ended March 31, 2024, and includes a press release as Exhibit 99.1. The text explicitly states that the press release is being furnished and incorporated by reference, and the document is relatively short (4166 characters). This indicates it is an announcement of quarterly financial results rather than the full quarterly report itself. The Form 8-K is commonly used for current reports including earnings releases. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2024-05-09 English
ARS
Annual Report
2024-04-29 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.